Please provide your email address to receive an email when new articles are posted on . The Eyhance monofocal IOL showed better tolerance to induced astigmatism than a standard monofocal IOL. This can ...
Enhanced monofocal IOLs may improve intermediate vision and preserve visual function in glaucoma patients. The study showed significant improvements in BCVA, RNFLT, and IOP for both enhanced and ...
Among many presentations during a hot topics session at the American Academy of Ophthalmology 2021 annual meeting, speakers discussed the first FDA approved therapy for thyroid eye disease and the ...
FORT WORTH, Texas--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced results from a new study presented at the ...
Please provide your email address to receive an email when new articles are posted on . Significantly more patients with multifocal IOLs were spectacle-free for near tasks than those with monofocal ...
FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...
Randomization (2:1:1) compared 78 mcg or 39 mcg BIM-IOL plus artificial tears versus standard monofocal IOL plus twice-daily timolol, with IOP change assessed at early visits. Mean IOP reduction at 12 ...
The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...
VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results